SCHEMBL1338965

SCHEMBL1338965

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(C(=O)CBr)ccc3[nH]c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.38
▸ GSK3B P49841 1/20 0.37
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ CNR1 P21554 7/20 0.35
▸ CNR2 P34972 7/20 0.35
▸ CA12 O43570 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ F2RL3 Q96RI0 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ ADRA2C P18825 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3135430 0.90 JAK2 (0.38) GSK3BJAK2JAK1TYK2JAK3
Hydrochloric Acid SCHEMBL1338631 0.89 JAK2 (0.38) GSK3BJAK2JAK1TYK2JAK3
SCHEMBL1338853 0.87 CNR1 (0.41) JAK2JAK1TYK2JAK3CNR1
SCHEMBL1337089 0.83 JAK2 (0.39) JAK2JAK1TYK2JAK3CNR1
SCHEMBL1339199 0.81 EPHX2 (0.37) PARP1JAK2JAK1TYK2JAK3
SCHEMBL1337009 0.80 GSK3B (0.38) GSK3BCNR1CNR2ALDH1A1F2RL3
SCHEMBL958804 0.80 F2RL3 (0.46) CNR1CNR2CA12CA9ALDH1A1
SCHEMBL1338067 0.78 KDM4E (0.48) GSK3BALDH1A1MEN1KMT2AF2RL3
SCHEMBL1340487 0.77 KDM4E (0.43) CNR1CNR2MEN1KMT2AF2RL3
SCHEMBL1338675 0.73 CNR1 (0.37) CNR1CNR2F2RL3EGFRALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 PARP1 370/4885GSK3B 691/4885JAK2 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback